Clinical Trial

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-01-16; most recent amendment 2024-12-19.
Status change: Not Yet Recruiting → Recruiting 2023-05-21
Trial Details
NCT Number NCT05698459
Lead Sponsor Binhui Biopharmaceutical Co., Ltd.
Conditions Advanced Liver Cancer
Enrollment 12 participants
Start Date 2023-05-05
Primary Completion 2025-08 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-20